BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

455 related articles for article (PubMed ID: 31887282)

  • 1. Comparative Safety and Effectiveness of Inhaled Corticosteroid and Long-Acting β
    Chang TY; Chien JY; Wu CH; Dong YH; Lin FJ
    Chest; 2020 May; 157(5):1117-1129. PubMed ID: 31887282
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative Effectiveness and Safety of Different Types of Inhaled Long-Acting β
    Wang MT; Lai JH; Huang YL; Liou JT; Cheng SH; Lin CW; Pan HY; Hsu YJ; Tsai CL
    Chest; 2021 Oct; 160(4):1255-1270. PubMed ID: 34023320
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Versus Other Inhaled Corticosteroid/Long-Acting Muscarinic Antagonist/Long-Acting β
    Ferguson GT; Darken P; Ballal S; Siddiqui MK; Singh B; Attri S; Holmgren U; de Nigris E
    Adv Ther; 2020 Jun; 37(6):2956-2975. PubMed ID: 32335859
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined corticosteroid and long-acting beta(2)-agonist in one inhaler versus long-acting beta(2)-agonists for chronic obstructive pulmonary disease.
    Nannini LJ; Lasserson TJ; Poole P
    Cochrane Database Syst Rev; 2012 Sep; 2012(9):CD006829. PubMed ID: 22972099
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Severe exacerbation and pneumonia in COPD patients treated with fixed combinations of inhaled corticosteroid and long-acting beta2 agonist.
    Yang HH; Lai CC; Wang YH; Yang WC; Wang CY; Wang HC; Chen L; Yu CJ
    Int J Chron Obstruct Pulmon Dis; 2017; 12():2477-2485. PubMed ID: 28860742
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparing a fixed combination of budesonide/formoterol with other inhaled corticosteroid plus long-acting beta-agonist combinations in patients with chronic obstructive pulmonary disease: a review.
    Solidoro P; Patrucco F; Bagnasco D
    Expert Rev Respir Med; 2019 Nov; 13(11):1087-1094. PubMed ID: 31498714
    [No Abstract]   [Full Text] [Related]  

  • 7. An innovative corticosteroid/long-acting β
    Usmani O; Roche N; Marshall J; Danagher H; Price D
    Expert Opin Drug Deliv; 2019 Dec; 16(12):1367-1380. PubMed ID: 31752560
    [No Abstract]   [Full Text] [Related]  

  • 8. Chronic Obstructive Pulmonary Disease Exacerbations and Pneumonia Hospitalizations Among New Users of Combination Maintenance Inhalers.
    Feldman WB; Avorn J; Kesselheim AS; Gagne JJ
    JAMA Intern Med; 2023 Jul; 183(7):685-695. PubMed ID: 37213116
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined corticosteroid and long-acting beta(2)-agonist in one inhaler versus inhaled corticosteroids alone for chronic obstructive pulmonary disease.
    Nannini LJ; Poole P; Milan SJ; Kesterton A
    Cochrane Database Syst Rev; 2013 Aug; 2013(8):CD006826. PubMed ID: 23990350
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease.
    Kew KM; Seniukovich A
    Cochrane Database Syst Rev; 2014 Mar; 2014(3):CD010115. PubMed ID: 24615270
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhaled corticosteroids versus long-acting beta(2)-agonists for chronic obstructive pulmonary disease.
    Spencer S; Evans DJ; Karner C; Cates CJ
    Cochrane Database Syst Rev; 2011 Oct; (10):CD007033. PubMed ID: 21975759
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of single-inhaler extrafine triple therapy versus inhaled corticosteroid plus long-acting beta2 agonist in eastern Asian patients with COPD: the TRIVERSYTI randomised controlled trial.
    Zheng J; Baldi S; Zhao L; Li H; Lee KH; Singh D; Papi A; Grapin F; Guasconi A; Georges G
    Respir Res; 2021 Mar; 22(1):90. PubMed ID: 33757520
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Asthma control in patients receiving inhaled corticosteroid and long-acting beta2-agonist fixed combinations. A real-life study comparing dry powder inhalers and a pressurized metered dose inhaler extrafine formulation.
    Müller V; Gálffy G; Eszes N; Losonczy G; Bizzi A; Nicolini G; Chrystyn H; Tamási L
    BMC Pulm Med; 2011 Jul; 11():40. PubMed ID: 21762500
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhaled corticosteroids versus long-acting beta(2)-agonists for chronic obstructive pulmonary disease.
    Spencer S; Karner C; Cates CJ; Evans DJ
    Cochrane Database Syst Rev; 2011 Dec; 2011(12):CD007033. PubMed ID: 22161409
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative effectiveness and safety of inhaled corticosteroid plus long-acting β
    Su VY; Ding TL; Chang YL; Chou YC; Hwang HE; Chou CY; Hsu CC
    Expert Rev Clin Pharmacol; 2024; 17(2):157-164. PubMed ID: 38224017
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differences in the efficacy and safety among inhaled corticosteroids (ICS)/long-acting beta2-agonists (LABA) combinations in the treatment of chronic obstructive pulmonary disease (COPD): Role of ICS.
    Latorre M; Novelli F; Vagaggini B; Braido F; Papi A; Sanduzzi A; Santus P; Scichilone N; Paggiaro P
    Pulm Pharmacol Ther; 2015 Feb; 30():44-50. PubMed ID: 25445928
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-world effectiveness of umeclidinium/vilanterol versus fluticasone propionate/salmeterol as initial maintenance therapy for chronic obstructive pulmonary disease (COPD): a retrospective cohort study.
    Moretz C; Sharpsten L; Bengtson LG; Koep E; Le L; Tong J; Stanford RH; Hahn B; Ray R
    Int J Chron Obstruct Pulmon Dis; 2019; 14():1721-1737. PubMed ID: 31534326
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of COPD-related outcomes in patients initiating a once daily or twice daily ICS/LABA.
    Stanford RH; Parker ED; Reinsch TK; Buikema AR; Blauer-Peterson C
    Respir Med; 2019 Apr; 150():1-7. PubMed ID: 30961933
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of inhaled corticosteroids /long-acting agonists in a single inhaler versus inhaled corticosteroids alone on all-cause mortality, pneumonia, and fracture in chronic obstructive pulmonary disease: A nationwide cohort study 2002-2013.
    Cho KH; Kim YS; Linton JA; Nam CM; Choi Y; Park EC
    Respir Med; 2017 Sep; 130():75-84. PubMed ID: 29206637
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The comparative effectiveness of initiating fluticasone/salmeterol combination therapy via pMDI versus DPI in reducing exacerbations and treatment escalation in COPD: a UK database study.
    Jones R; Martin J; Thomas V; Skinner D; Marshall J; Stagno d'Alcontres M; Price D
    Int J Chron Obstruct Pulmon Dis; 2017; 12():2445-2454. PubMed ID: 28860739
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.